| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Liminatus Pharma, Inc.
$0.11
0 (-2.69%)
Market Cap
4.87 M
EPS
-0.44
P/E Ratio
-
Value Trade
744.26 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
400.00 K
Operating CF
-2.02 M
Total Assets
2.79 M
Total Liabilities
2.92 M
Equity
-132.60 K
9.71 %
Week
4.83 %
1 Month
-41.03 %
3 Month
-77.63 %
6 Month
-98.39 %
5 Year
-98.39 %
All Time
Cash Data
Cash Position
1.91 M
Monthly Burn
672.00 K
Runway
0.1 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
1.16 M
52 Week Range
0.10 - 4.85
% held by Insiders
41.73 %
% held by Institutions
2.17 %
Enterprise Value
4.40 M
Total Shares
44.90 M
Short %
12.64 %
Float Shares
33.49 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Liminatus Pharma, Inc.
2Total events
0Upcoming
2Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LIMN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LIMN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LIMN▼ -2.7%today
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma has successfully transferred its stock listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026. The Nasdaq Hearings Panel has granted the company additional time until September 3, 2026, to comply with the minimum bid price requirement. The company is committed to taking necessary actions to regain compliance while continuing its clinical development efforts.
Read more →LIMNLiminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma has amended its merger agreement with InnocsAI to expedite the closing process, now expected on July 2, 2026. The deal includes a mix of common stock and non-voting convertible preferred stock, valued at approximately $320 million. This merger aims to enhance Liminatus' oncology pipeline and create strategic partnerships in cancer therapy.
Read more →LIMN▼ -22.2%on this news
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma has entered into a warrant exercise agreement, raising $1.9 million from existing investors. The agreement involves the exercise of 10,344,000 shares of common stock and the issuance of new warrants for 20,688,000 shares. The new warrants have an exercise price of $0.18 and require stockholder approval before they can be exercised.
Read more →LIMN▼ -31.1%on this news
Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma has received a delisting notification from Nasdaq due to failure to meet market value requirements. The company was given a grace period to regain compliance but did not succeed. Unless an appeal is filed by May 27, 2026, trading of its securities will be suspended on May 29, 2026. The company intends to appeal the decision.
Read more →LIMN▲ +31%on this newsshared move
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma has announced a merger with InnocsAI to enhance its oncology cell therapy pipeline. The merger will involve the acquisition of multiple biologic and cellular therapy assets aimed at addressing challenges in hematologic cancers and solid tumors. The transaction is valued at approximately $320 million and is expected to provide development opportunities across various cancer indications.
Read more →LIMN▼ -31.9%on this news
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Liminatus Pharma, Inc. announced the pricing of a public offering of 13,813,000 shares at $0.29 each, aiming to raise $4.0 million. The offering includes warrants for additional shares, potentially raising $6.0 million. The funds will support working capital and business objectives. The closing is expected on February 18, 2026.
Read more →LIMNLiminatus Pharma Announces Receipt of Nasdaq Listing Delinquency Letter
Liminatus Pharma has announced that it received a Nasdaq Listing Delinquency Letter due to a delay in filing its Quarterly Report on Form 10-Q. The letter does not immediately affect its stock listing as it retains its trading status on Nasdaq. The company is required to submit a plan for regaining compliance within 60 days, with a potential extension available if approved. This compliance challenge occurs as the company seeks to advance its immunotherapy drug, IBA101, targeting cancer. Investors should be aware of the uncertainties that may impact the company's future compliance with Nasdaq regulations.
Read more →LIMN▼ -6.4%on this news
IBA101: The Strategic Answer to the PD-1/L1 Patent Cliff Liminatus Pharma, Inc. (the "Company") believes that the immuno-oncology landscape is approaching a critical inflection point. Since their first approval in 2014,
Liminatus Pharma, Inc. is addressing the impending patent expirations of PD-1/PD-L1 inhibitors with its next-generation CD47 monoclonal antibody, IBA101. The company believes IBA101 could synergize effectively with current therapies, enhancing their effectiveness while offering a favorable safety profile. As major players face the entry of biosimilars, Liminatus highlights the strategic value of its unique approach and established safety in the rapidly evolving immuno-oncology market. The success of IBA101 could alter the competitive dynamics by prolonging the lifecycle of existing PD-1/PD-L1 franchises.
Read more →LIMN▲ +33.4%on this news· ran to -53% by day 3
Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101 Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy La Palma, Ca, United St
Liminatus Pharma is advancing its next-generation CD47 inhibitor, IBA101, towards human trials in the U.S. and Korea. With a focus on eliminating side effects seen in earlier CD47 candidates, IBA101 is designed to target tumor cells while sparing red blood cells and platelets. The company is preparing to submit its investigational new drug applications and has partnered with a lung cancer specialist for enhanced patient access and research capabilities. Liminatus expects the trials to start by 2027, aiming to reshape immunotherapy approaches in cancer treatment.
Read more →LIMN▲ +33.4%on this news· ran to -53% by day 3
Crafting the Future of Healing for Patients Next Generation CD47 Blockade with Liminatus Pharma, Innobation Bio Disclaimer This presentation (this "Presentation") has been assembled by Liminatus Pharma Limited, including
Liminatus Pharma is advancing its next-generation CD47 blockade therapy, IBA101, aimed at improving cancer treatment outcomes. The company highlights its experienced leadership, preclinical successes, and strategic plans for partnerships with major pharmaceutical firms like AstraZeneca and Merck. Preparations for a Phase 1 clinical trial are underway, demonstrating clear milestones for growth. Risks associated with regulatory approvals and market conditions remain, but Liminatus retains a strong financial position and a clear roadmap for future developments.
Read more →LIMN▲ +139.8%on this news· ran to +391% by day 3
Liminatus Pharma Announces Compliance with Nasdaq Filing Requirements
Liminatus Pharma, Inc. has announced its compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Quarterly Report on Form 10-Q. The notice of compliance was received on June 3, 2025, following a previous notification letter indicating non-compliance due to a delayed filing. With this resolution, Liminatus aims to focus on its development of innovative cancer therapies, particularly its CD47 monoclonal antibody candidate, IBA101.
Read more →LIMN▼ -23.6%on this news
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholder of Iris Parent Holding Corp.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidat
Iris Parent Holding Corp. has received an audit opinion confirming that its consolidated financial statements fairly present its financial position. However, the report highlights significant concerns over the Company's ability to continue as a going concern due to a lack of substantive operations and sufficient cash reserves. As of December 31, 2024, the Company reported an accumulated deficit and substantial liabilities, raising doubts about its future viability. Management's plans regarding these financial uncertainties are noted but not detailed in the document.
Read more →Competitive Position
How LIMN ranks across every disease it competes inCompetitive Position is a premium feature
See how LIMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial